Summary
Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety.
It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections.
Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technology. The product is named XAV-19 and is expected to treat patients suffering from moderate to severe pneumonia.
The purpose of BRIGHT is to prepare the product, run all necessary investigation so that we can safely run a clinical trial demonstrating the efficacy of the product. This will be a phase 2 double-blind clinical trial of XAV19 versus placebo. The endpoint will be the quick recovery of patients admitted at the hospital.
It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections.
Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technology. The product is named XAV-19 and is expected to treat patients suffering from moderate to severe pneumonia.
The purpose of BRIGHT is to prepare the product, run all necessary investigation so that we can safely run a clinical trial demonstrating the efficacy of the product. This will be a phase 2 double-blind clinical trial of XAV19 versus placebo. The endpoint will be the quick recovery of patients admitted at the hospital.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/962036 |
| Start date: | 01-08-2020 |
| End date: | 31-12-2022 |
| Total budget - Public funding: | 3 127 625,00 Euro - 2 162 650,00 Euro |
Cordis data
Original description
Since 2014 XENOTHERA has developed a platform for producing Glyco-Humanized Polyclonal Antibodies (GH-pAb) with high efficiency and optimized safety.It has been known for decades that polyclonal antibodies are very efficient weapons in infectious diseases, either bacterial or viral, and they are established as superior to monoclonal in various viral infections.
Since the beginning of the pandemic XENOTHERA has initiated a project to develop a new treatment against COVID-19 based on its technology. The product is named XAV-19 and is expected to treat patients suffering from moderate to severe pneumonia.
The purpose of BRIGHT is to prepare the product, run all necessary investigation so that we can safely run a clinical trial demonstrating the efficacy of the product. This will be a phase 2 double-blind clinical trial of XAV19 versus placebo. The endpoint will be the quick recovery of patients admitted at the hospital.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Search
